Finland Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Finland Pharmaceuticals and Healthcare Report

Finland Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Finland Pharmaceuticals and Healthcare Report
Published Sep 03, 2016
70 pages — Published Sep 03, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In July ----, Finland s Faron Pharmaceuticals entered into an agreement with Abzena whereby Abzena will manufacture Clevegen, a novel therapeutic antibody being developed by Faron to reduce immune suppression in cancer. In July ----, the National Coalition Party received criticism for its apparent reluctance to de-regulate and increase competition in the pharmacy industry. ...In July ----, the National Coalition Party received criticism for its apparent reluctance to de-regulate and increase competition in the pharmacy industry. Also in July ----, Finnish pharmaceutical manufacturers began testing new medicine packaging in preparation for new EU-wide measures targeting counterfeit medicines. In June ----, Weifa signed a five-year distribution agreement with the Finland-based Fysioline Group covering several of Weifa s most recently launched products within the pain category, and can be extended to include additional products. ...Also in July ----, Finnish pharmaceutical manufacturers began testing new medicine packaging in preparation for new EU-wide measures targeting counterfeit medicines. In June ----, Weifa signed a five-year distribution agreement with the Finland-based Fysioline Group covering several of Weifa s most recently launched products within the pain category, and can be extended to include additional products.

...Finland s Risk/Reward Index score for Q--- remains unchanged from last quarter, at --.- out of ---. However, the country has fallen from seventh to ninth position in our Western European matrix, just below Norway (--.-) and above Sweden (--.-). ...However, the country has fallen from seventh to ninth position in our Western European matrix, just below Norway (--.-) and above Sweden (--.-). Finland s strong emphasis on the regulatory environment is an appealing feature of the market, although a major factor affecting the business environment for drugmakers is its small overall market size. Increasing cost-containment measures also negatively affect the Industry Rewards score. ...Increasing cost-containment measures also negatively affect the Industry Rewards score. Nevertheless, high per capita drug expenditure means that companies operating in the country can see substantial income.

...Obesity boom to substantially increase non-communicable disease burden. ...Threats Impact of forthcoming patent expirations. As the government copies other European governments cost-containment measures operating conditions for drugmakers will become tougher over the long term. Despite a sluggish start, the potential of the domestic generics market will increasingly attract strong foreign competition, both from Europe and further afield. ...

  
Source:
Document ID
2052-5044
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Finland Pharmaceuticals and Healthcare Report" Sep 03, 2016. Alacra Store. Dec 03, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Finland-Pharmaceuticals-and-Healthcare-Report-2026-1446>
  
APA:
Business Monitor International - Industry Reports. (2016). Finland Pharmaceuticals and Healthcare Report Sep 03, 2016. New York, NY: Alacra Store. Retrieved Dec 03, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Finland-Pharmaceuticals-and-Healthcare-Report-2026-1446>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.